AbbVie Inc., a global biopharmaceutical company, is strategizing to maintain growth in a post-Humira era. The company holds leading positions in immunology, oncology, aesthetics, neuroscience, and eye care, with operations in over 70 countries. While its key product, Humira, faces increasing competition from biosimilars after losing exclusivity in 2023, the company is focused on growing newer immunology products, Skyrizi and Rinvoq. Additionally, AbbVie is expanding its portfolio through acquisitions, such as the recent purchase of Cerevel Therapeutics, and strategic collaborations.

Despite revenue decline due to Humira, the company reported strong sales for its newer products and remains committed to research and development, with approximately 90 compounds and indications in its pipeline. AbbVie's stock price has shown consistent growth over the past year, with technical indicators suggesting a robust uptrend. However, the company must navigate challenges like the Inflation Reduction Act’s impact on profitability, competition from biosimilars, and the success of integrating acquisitions.